1. Home
  2. CTS vs ZYME Comparison

CTS vs ZYME Comparison

Compare CTS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTS Corporation

CTS

CTS Corporation

HOLD

Current Price

$56.65

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$27.66

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTS
ZYME
Founded
1896
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
CTS
ZYME
Price
$56.65
$27.66
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$38.90
AVG Volume (30 Days)
192.6K
499.9K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
0.29%
N/A
EPS Growth
15.87
33.33
EPS
0.59
N/A
Revenue
$541,318,000.00
$105,965,000.00
Revenue This Year
$5.55
$183.10
Revenue Next Year
$5.00
N/A
P/E Ratio
$95.14
N/A
Revenue Growth
4.95
38.87
52 Week Low
$36.03
$13.60
52 Week High
$69.55
$29.75

Technical Indicators

Market Signals
Indicator
CTS
ZYME
Relative Strength Index (RSI) 36.16 73.09
Support Level $54.75 $22.10
Resistance Level $59.66 $29.75
Average True Range (ATR) 1.87 1.10
MACD -0.89 0.57
Stochastic Oscillator 10.52 99.52

Price Performance

Historical Comparison
CTS
ZYME

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: